Company Filing History:
1 out of 5 
1 out of 1 
1 out of 15,471 
Years Active: 1997-2002
Title: Keiji Koda: Innovator in Monoclonal Antibodies
Introduction
Keiji Koda is a notable inventor based in Chiba, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 2 patents, Koda's work focuses on cancer research and diagnostics.
Latest Patents
Koda's latest patents include innovative methods related to carcinoma-associated antigen (SK1) monoclonal antibodies. These patents detail the production of antibodies specifically reactive with epitopes present on SK1. His work aims to enhance methods for detecting and ameliorating malignant diseases, showcasing the potential for improved cancer diagnostics and treatments.
Career Highlights
Throughout his career, Koda has worked with prominent companies in the biotechnology sector. Notable among these are Viventia Biotech Inc. and SciClone, Inc. His experience in these organizations has contributed to his expertise in monoclonal antibody development and cancer research.
Collaborations
Koda has collaborated with esteemed colleagues, including Mark C. Glassy and Helena R. Chang. These partnerships have furthered his research and innovation in the field of biotechnology.
Conclusion
Keiji Koda's contributions to the development of monoclonal antibodies represent a significant advancement in cancer research. His innovative patents and collaborations highlight his commitment to improving diagnostic methods and treatments for malignant diseases.